Skip to content
    Clinical Trials

    Robotic PC-RPLND shows similar relapse-free survival to open surgery in matched cohort

    Chavarriaga et alWorld Journal of Urology

    Robotic PC-RPLND shows similar relapse-free survival to open surgery in matched cohort
    In a multicenter propensity score-matched study across 11 academic medical centers analyzing patient data from 1990 to 2023, researchers evaluated perioperative and oncologic outcomes of robotic versus open post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for testicular cancer. The study established a 1:1 matched cohort comprising 134 robotic cases and 134 open cases. The primary endpoint was time to relapse, evaluated via Kaplan-Meier relapse-free survival (RFS) analysis and Cox proportional hazards modeling adjusting for template and pathology. Secondary endpoints included operative duration, length of hospital stay, estimated blood loss, lymph node yield, and surgical complication rates. At a median follow-up of 2.2 years, 3-year estimated RFS was similar between the robotic and open groups (92.8% vs. 88.5%, p = 0.18). Relapse occurred in 5.2% of robotic cases compared to 12.3% of open cases, with the majority of recurrences taking place within the first post-operative year. Lymph node yield and the presence of viable tumor were comparable between both surgical approaches. Perioperative outcomes favored the robotic approach, which demonstrated lower estimated blood loss, reduced hospital length of stay, and half the overall complication rate of open surgery (16.4% vs. 32.1%). Notably, the robotic cohort experienced a 0% rate of ileus compared to 12.7% in the open cohort. The primary study limitation identified by the authors was its retrospective design. The authors concluded that with proper patient selection and surgical expertise in specialized academic settings, robotic PC-RPLND offers significantly reduced morbidity and superior perioperative outcomes while maintaining equivalent short-term oncologic control relative to open dissection.

    Key Takeaways

    • In a 1:1 propensity score-matched cohort of 268 patients, 3-year estimated relapse-free survival was comparable between robotic and open post-chemotherapy retroperitoneal lymph node dissection (92.8% vs. 88.5%, p = 0.18), with relapse rates of 5.2% for robotic vs. 12.3% for open approaches.
    • Robotic PC-RPLND significantly reduced overall surgical complication rates compared with open surgery (16.4% vs. 32.1%), including a 0% rate of post-operative ileus versus 12.7% in the open cohort, as well as lower estimated blood loss and shorter length of hospital stay.
    • Lymph node yield and viable tumor rates were comparable between surgical modalities, supporting robotic PC-RPLND as an oncologically equivalent, lower-morbidity option when performed with appropriate patient selection at experienced academic centers.
    Read the original sourceWorld Journal of Urology